LMR Partners LLP Purchases 4,059 Shares of Glaukos Co. (NYSE:GKOS)

LMR Partners LLP boosted its position in shares of Glaukos Co. (NYSE:GKOS) by 12.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 36,986 shares of the medical instruments supplier’s stock after buying an additional 4,059 shares during the quarter. LMR Partners LLP owned approximately 0.07% of Glaukos worth $4,819,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. EFG Asset Management North America Corp. increased its position in shares of Glaukos by 0.5% in the 2nd quarter. EFG Asset Management North America Corp. now owns 27,205 shares of the medical instruments supplier’s stock valued at $3,216,000 after buying an additional 128 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Glaukos in the 3rd quarter valued at about $25,000. New York State Teachers Retirement System lifted its stake in Glaukos by 0.4% in the 3rd quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier’s stock valued at $6,272,000 after purchasing an additional 200 shares during the last quarter. KBC Group NV lifted its stake in Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 201 shares during the last quarter. Finally, Inspire Investing LLC lifted its stake in Glaukos by 6.9% in the 3rd quarter. Inspire Investing LLC now owns 3,193 shares of the medical instruments supplier’s stock valued at $416,000 after purchasing an additional 206 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Buying and Selling at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 5,000 shares of Glaukos stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total transaction of $646,800.00. Following the transaction, the chief operating officer now owns 102,169 shares of the company’s stock, valued at $13,216,581.84. The trade was a 4.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the transaction, the director now directly owns 32,336 shares in the company, valued at $4,225,345.12. This represents a 8.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,275 shares of company stock valued at $1,354,967 over the last 90 days. 6.40% of the stock is currently owned by corporate insiders.

Glaukos Trading Down 1.2 %

NYSE:GKOS opened at $136.79 on Tuesday. The company has a 50-day moving average price of $130.92 and a 200-day moving average price of $122.57. Glaukos Co. has a 12 month low of $59.22 and a 12 month high of $145.84. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The stock has a market cap of $7.54 billion, a price-to-earnings ratio of -45.29 and a beta of 1.02.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. The business had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. Glaukos’s revenue was up 23.9% compared to the same quarter last year. During the same period last year, the business earned ($0.50) EPS. Equities analysts predict that Glaukos Co. will post -1.96 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on GKOS. BTIG Research raised their price objective on shares of Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. JPMorgan Chase & Co. lifted their price objective on shares of Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. StockNews.com raised shares of Glaukos from a “sell” rating to a “hold” rating in a research note on Monday, October 21st. Truist Financial boosted their target price on shares of Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, Piper Sandler set a $140.00 target price on shares of Glaukos in a research note on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.55.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.